| Literature DB >> 32147707 |
Nicolas Mirlesse1, Kristof Egervari2,3, Aurélie Bornand2, Julien Lecluse1, Johannes A Lobrinus2, Max Scheffler4, Christine Serratrice1, Virginie Prendki1, Clémence Cuvelier1.
Abstract
Statins are widely prescribed in the treatment of hypercholesterolemia. While their efficacy in the secondary prevention of vascular events is proven, their safety profile in older patients with multiple co-morbidities and polypharmacy remains questionable. Although rare, antihydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy is a severe adverse effect of statins, manifesting as myalgias, proximal muscle weakness, muscle cell necrosis and rhabdomyolysis. We report an uncommon case of an autopsy-proven anti-HMGCR necrotising myopathy predominately affecting pharyngeal muscles in an older patient, leading to dysphagia, pneumonia and death within 3 weeks from onset. Clinicians should screen for dysphagia in any patient with suspected anti-HMGCR myopathy, order an anti-HMGCR antibody titre and consider prompt immunosupressive therapy.Entities:
Keywords: anti-HMGCR necrotising myopathy; dysphagia; older patients; pharyngeal muscles necrosis; statins
Mesh:
Substances:
Year: 2020 PMID: 32147707 DOI: 10.1093/ageing/afaa038
Source DB: PubMed Journal: Age Ageing ISSN: 0002-0729 Impact factor: 10.668